Navigation Links
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Date:10/5/2009

GAITHERSBURG, Md., Oct. 5, /PRNewswire-FirstCall/ -- Schering-Plough Corp. (NYSE: SGP) announced today that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

PEGINTRON is a longer-acting form of the protein interferon alfa-2b (INTRON® A). PEGINTRON is administered subcutaneously once-weekly via self-injection.

"Treating malignant melanoma remains a challenge given the limited treatment options that are currently available," said John M. Kirkwood, M.D., Director of the Melanoma Center and Professor and Chief of the Division of Medical Oncology at the University of Pittsburgh School of Medicine, Pittsburgh. "Today's positive recommendation of pegylated interferon alfa-2b by the committee represents an important step toward a potential new option in the treatment of Stage III malignant melanoma, especially as the incidence of the disease continues to increase."

The FDA generally follows the recommendations of its advisory committees, although it is not required to do so. Schering-Plough filed the supplemental Biologics License Application (sBLA) for this indication to the FDA in September 2007.

"The committee's positive recommendation for PEGINTRON is an encouraging development toward the future treatment of melanoma," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "Schering-Plough remains committed to developing new therapies for the treatment of malignant melanoma, as well as for advancing the understanding and prevention of this aggressive form of cancer."

About Malignant Melanoma

Malignant melanom
'/>"/>

SOURCE Schering-Plough Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
3. CryoCor Invited to Participate in FDA Advisory Panel Meeting on Atrial Fibrillation
4. Patient Safety Authority Board of Directors Names Infection Advisory Panel
5. Broker a Suite of Research & Advisory Services to Enhance Human Resources
6. Lynn Clark Callister, National Leader in Maternal-Child Health Nursing, Joins March of Dimes Advisory Council
7. MaxLife Fund Corp. appoints Daniel E. Kahan, to its Advisory Board
8. Delta Dental Plans Association Forms National Scientific Advisory Committee
9. Alter+Care Creates the Advisory Board
10. Patient Safety Authority Releases Advisory Focusing on Common Causes of Medication Errors
11. Susan G. Komen for the Cure Appoints Dr. Amelie G. Ramirez to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 “You have a ... than 500 people and their loved ones across the U.S. ... a brain tumor diagnosis is typically met with confusion and ... new and difficult vocabulary, and make critical decisions about a ... tumor diagnosis is accompanied by a sense of isolation and ...
(Date:7/25/2014)... The North America Artificial lift market report defines ... analysis and forecast of revenue. The artificial lift market in ... in 2013 to around $7 billion by 2018, at a ... through the TOC of North America artificial lift market report, ... provides a glimpse of the segmentation in North America Artificial ...
(Date:7/25/2014)... Providence, RI (PRWEB) July 25, 2014 ... Island Quality Improvement Organization (QIO) was recently awarded ... from the Centers for Medicare & Medicaid Services ... to fourteen organizations across the United States, represent ... In order to successfully execute the contract initiatives, ...
(Date:7/25/2014)... Health Advocate™, Inc., the nation’s leading healthcare ... Corporation, is introducing its newest solution in an upcoming ... Quality. , The webinar will be held twice on ... at 2 PM ET. For more information or to ... or call 866.799.2655. , In an environment of escalating ...
(Date:7/25/2014)... July 25, 2014 -- The Elizabeth Glaser Pediatric ... between the Medicines Patent Pool (MPP) and Gilead ... fumarate (TAF), a promising new HIV medication. The ... Conference (AIDS 2014) in Melbourne, Australia. , ... trials, early data suggests it could be a ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 2Health News:American Brain Tumor Association to Expand Service Reach with Launch of Nationwide Volunteer Network 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Artificial Lift Services Market is Expected to Reach $7 Billion in 2018 - New Report by MicroMarket Monitor 4Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 2Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 3Health News:Healthcentric Advisors and Qualidigm Partner to Improve the Healthcare Quality for New England 4Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3
... updated the NCCN Guidelines for Venous Thromboembolic Disease, which ... (PE), and is a common condition in people with ... graduated compression stockings in prophylaxis and treatment, and a ... May 20 The National Comprehensive Cancer Network (NCCN) ...
... Alliance designed to benefit Californians with medical ... Medical Association (CMA), representing 35,000 physicians in ... the MedicAlert Foundation, the leading nonprofit providing ... teamed up to provide patients living with ...
... counseling also proved cost-effective, study finds , , WEDNESDAY, ... program that promoted exercise, healthy eating and quitting ... to moderate chronic obstructive pulmonary disease (COPD) and ... patients in the study were randomly assigned to ...
... Market is Reflected in Burgeoning Pipeline of More than ... from Decision ResourcesWALTHAM, Mass., May 20 Decision Resources, ... for pharmaceutical and healthcare issues, finds that the launch ... over the next 10 years will drive the type ...
... partnership with Axway to provide innovative solutions ... technologists to address the challenges of implementing ... cost-effective manner.BELLEVUE, Wash., May 20 Edifecs, ... simplification and systems interoperability, and Axway, a ...
... Directors of BD (Becton, Dickinson and Company) (NYSE: ... per common share, payable on June 30, 2009 to holders ... rate is $1.32 per share. About BD BD is ... sells medical devices, instrument systems and reagents. The Company is ...
Cached Medicine News:Health News:NCCN Updates Supportive Care Guidelines for VTE 2Health News:NCCN Updates Supportive Care Guidelines for VTE 3Health News:California Medical Association Joins MedicAlert Foundation to Offer Medical Identification for Members and Patients 2Health News:Healthier Lifestyle Can Cut COPD Symptoms 2Health News:The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 2Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 3Health News:Edifecs(TM) and Axway Announce a Partnership Targeting Innovative HIPAA 5010 Migration Solutions. 4
(Date:7/24/2014)... VIEW, Calif. , July 24, 2014 /PRNewswire/ ... a leading provider of medication and supply management ... a conference call Thursday, July 31, to discuss ... , Omnicell Second Quarter 2014 earnings conference ... 1:30 p.m. PTWho:  , Randall Lipps, chairman, president ...
(Date:7/24/2014)... and MENLO PARK, Calif. , July 24, ... ("DelMar" "the company") announced today that the company,s board of ... December 31 to June 30. Accordingly, DelMar will file a ... Jeffrey Bacha , president and CEO of DelMar ... step in achieving our goal of obtaining a senior exchange ...
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 2DelMar Pharmaceuticals Announces Change of Fiscal Year End and Provides Update on Glioblastoma Clinical Trial 3LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2
... , HUNTINGTON BEACH, California and ... cancer diagnostics, today announced the,inclusion of its breast cancer ... on the primary therapy of early breast,cancer. The recommendations ... will appear in the August print edition. , ...
... LAUSANNE, Switzerland, June 23 Debiopharm Group,(Debiopharm), ... on the development of prescription drugs that target unmet ... names Moapar(R),and Salvapar(R)), was launched in Germany in May ... was also launched on a preliminary basis in,Belgium. The ...
Cached Medicine Technology:Agendia's Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations 2Salvacyl(R), Developed by Debiopharm, is Launched in two European Countries 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: